drugset / Trial / NCT02489123
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2
Terminated
8 enrolled
University of Washington
National Cancer Institute (NCI) · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgen made by the body.
Timeline
- Start
- 2015-08-11
- Primary completion
- 2020-06-16
- Completion
- 2020-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | — | Oral |